Engineered Antimicrobial Peptides for Resistant Bacteria
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The emergence of antibiotic-resistant bacterial strains threatens the management of infectious diseases, necessitating the development of new antimicrobial agents that can effectively target a broad range of pathogens, including those resistant to current antibiotics.
Innovation Solution
Development of engineered antimicrobial peptides derived from the lentiviral transmembrane protein cytoplasmic tail, such as LLP1 and its analogs, which exhibit potent antibacterial activity by disrupting bacterial membranes while maintaining selectivity for bacterial cells over mammalian cells, and can be used as coatings on medical devices to prevent biofilm formation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional antibiotics are used to treat bacterial infections, then effective treatment is achieved for susceptible bacteria, but treatment fails against antibiotic-resistant bacterial strains
Solution Approach 1:
The patent modifies the amino acid sequence of the parent LLP1 peptide to create analogs with optimized parameters. Specifically, Arginine residues are substituted at positions 2, 5, and 8 to enhance cationic character and amphipathicity, while maintaining the core structure. These parameter changes enable the peptides to effectively target antibiotic-resistant bacteria while preserving selectivity for bacterial cells over mammalian cells.
Solution Approach 2:
The engineered peptides represent a composite approach combining elements of viral-derived sequences with optimized antimicrobial motifs. The peptides integrate cationic amino acids (Arginine, Lysine) with hydrophobic residues to create an amphipathic structure that combines membrane-disrupting capability with selective toxicity, effectively creating a new class of antimicrobial agents with broad-spectrum activity against resistant pathogens.
2Strength
If antimicrobial peptides are designed to disrupt bacterial membranes, then potent antibacterial activity is achieved, but selectivity between bacterial and mammalian cells must be maintained
Solution Approach 1:
The patent applies local quality by creating distinct regions within the peptide structure with different properties. The peptides feature a cationic face rich in Arginine residues that interacts with negatively charged bacterial membranes, and a hydrophobic face that inserts into the membrane interior. This local differentiation of properties within the single peptide structure enables selective disruption of bacterial membranes while sparing mammalian cells with different membrane compositions.
Solution Approach 2:
The engineered peptides exhibit asymmetric amphipathic α-helical structure with unequal distribution of charged and hydrophobic residues. This asymmetry creates a pronounced cationic face and hydrophobic face, allowing the peptide to preferentially interact with and disrupt anionic bacterial membranes while having minimal effect on zwitterionic mammalian cell membranes, thus maintaining high selectivity and reduced toxicity.
3Reliability
If peptides are engineered with enhanced potency against resistant bacteria, then antimicrobial activity is improved, but complexity of peptide design and synthesis increases
Solution Approach 1:
The patent employs segmentation by dividing the 28-residue LLP1 parent sequence into functional segments: an N-terminal region with Arginine substitutions for enhanced cationic character, a central hydrophobic core for membrane insertion, and a C-terminal region maintaining structural integrity. This segmentation allows systematic optimization of each region's properties to enhance activity against resistant bacteria while maintaining overall structural simplicity and feasibility of synthesis.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These peptides demonstrate broad-spectrum activity against resistant bacteria, including methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa, with enhanced potency and selectivity, and the ability to maintain activity in physiological conditions, making them effective against a range of pathogens and suitable for use on medical devices to prevent biofilm formation.
Implementation Method 1
The mechanism by which these peptides kill bacteria proceeds in a two step process, first binding to the negatively charged bacterial surface
Implementation Method 2
second by driving these bound peptides into the bacterial membrane. The culmination of these processes ultimately results in the disruption of the bacterial membranes structural integrity
Implementation Method 3
For gram-negative organisms, cationic antimicrobial peptides have the added advantage of binding lipopolysaccharide (LPS), thereby detoxifying its endotoxic activity
Data Source
Figure 1
Figure 2
Figure 3
AI summary
Described herein are peptides having antimicrobial activity (antimicrobial peptides). The antimicrobial peptides, designated LBU, WLBU and WR, are analogs of the Lentivirus Lytic Peptide 1 (LLP1) amino acid sequence. The antimicrobial peptides are monomers or multimers of peptides referred to as the Lytic Base Unit (LBU) peptides, derived from the LLP1 analogs and also having antimicrobial activity. Also decribed herein are using the peptides in a variety of contexts, including the treatment or prevention of infectious diseases. Methods of killing fungi, such as Candida and Cryptococcus species, and bacteria, such as B.anthracis, are provided herein. Methods of neutralizing enveloped viruses, such as poxvirus, herpesvirus, rhabdovirus, hepadnavirus, baculovirus, orthomyxovirus, paramyxovirus, retrovirus, togavirus, bunyavirus and flavivirus, including influenza virus and HIV-1 also are provided herein. Solid phase substrates and peptide-cargo complexes comprising the peptides also are provided.